Application of the Adaptive Validation Substudy Design to Colorectal Cancer Recurrence

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Zauber AG. The impact of screening on colorectal cancer mortality and incidence: has it really made a difference? Dig Dis Sci. 2015;60(3):681–691. doi:10.1007/s10620-015-3600-525740556
   PubMed Web of Science ®Google Scholar
• Welch HG, Robertson DJ. Colorectal cancer on the decline–why screening can’t explain it all. N Engl J Med. 2016;374(17):1605–1607. doi:10.1056/NEJMp160044827119236
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67(3):177–193. doi:10.3322/caac.2139528248415
   PubMed Web of Science ®Google Scholar
• Rex DK, Kahi CJ, Levin B, et al. Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and US multi-society task force on colorectal cancer. CA Cancer J Clin. 2006;56(3):160–167; quiz 185–166.
   Web of Science ®Google Scholar
• Abulafi AM, Williams NS. Local recurrence of colorectal cancer: the problem, mechanisms, management and adjuvant therapy. Br J Surg. 1994;81(1):7–19. doi:10.1002/(ISSN)1365-21688313126
   PubMed Web of Science ®Google Scholar
• Holmes AC, Riis AH, Erichsen R, et al. Descriptive characteristics of colon and rectal cancer recurrence in a Danish population-based study. Acta Oncol. 2017;56(8):1111–1119. doi:10.1080/0284186X.2017.130465028339306
   PubMed Web of Science ®Google Scholar
• Yoshii S, Nojima M, Nosho K, et al. Factors associated with risk for colorectal cancer recurrence after endoscopic resection of T1 tumors. Clin Gastroenterol Hepatol. 2014;12(2):292–302.e293. doi:10.1016/j.cgh.2013.08.00823962552
   PubMed Web of Science ®Google Scholar
• Primrose JN, Perera R, Gray A, et al. Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA. 2014;311(3):263–270. doi:10.1001/jama.2013.28571824430319
   PubMed Web of Science ®Google Scholar
• Walker AS, Johnson EK, Maykel JA, et al. Future directions for the early detection of colorectal cancer recurrence. J Cancer. 2014;5(4):272–280. doi:10.7150/jca.887124790655
   PubMed Web of Science ®Google Scholar
• Wille-Jorgensen P, Syk I, Smedh K, et al. Effect of more vs less frequent follow-up testing on overall and colorectal cancer-specific mortality in patients with stage II or III colorectal cancer: the COLOFOL randomized clinical trial. JAMA. 2018;319(20):2095–2103. doi:10.1001/jama.2018.562329800179
   PubMed Web of Science ®Google Scholar
• Punt CJ, Koopman M, Vermeulen L. From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nat Rev Clin Oncol. 2017;14(4):235–246. doi:10.1038/nrclinonc.2016.17127922044
   PubMed Web of Science ®Google Scholar
• Lash TL, Riis AH, Ostenfeld EB, et al. Associations of statin use with colorectal cancer recurrence and mortality in a Danish cohort. Am J Epidemiol. 2017;186(6):679–687. doi:10.1093/aje/kww24528338891
   PubMed Web of Science ®Google Scholar
• Schmidt M, Schmidt SAJ, Adelborg K, et al. The Danish health care system and epidemiological research: from health care contacts to database records. Clin Epidemiol. 2019;11:563–591. doi:10.2147/CLEP.S17908331372058
   PubMed Web of Science ®Google Scholar
• Lash TL, Riis AH, Ostenfeld EB, Erichsen R, Vyberg M, Thorlacius-Ussing O. A validated algorithm to ascertain colorectal cancer recurrence using registry resources in Denmark. Int J Cancer. 2015;136(9):2210–2215. doi:10.1002/ijc.v136.925307704
   PubMed Web of Science ®Google Scholar
• Spiegelman D, Rosner B, Logan R. Estimation and inference for logistic regression with covariate misclassification and measurement error in main study/validation study designs. J Am Stat Assoc. 2000;95(449):51–61.
   Web of Science ®Google Scholar
• Holcroft CA, Spiegelman D. Design of validation studies for estimating the odds ratio of exposure-disease relationships when exposure is misclassified. Biometrics. 1999;55(4):1193–1201. doi:10.1111/j.0006-341X.1999.01193.x11315067
   PubMed Web of Science ®Google Scholar
• Holford TR, Stack C. Study design for epidemiologic studies with measurement error. Stat Methods Med Res. 1995;4(4):339–358. doi:10.1177/0962280295004004058745130
   PubMedGoogle Scholar
• Ingeholm P, Gogenur I, Iversen LH. Danish colorectal cancer group database. Clin Epidemiol. 2016;8:465–468. doi:10.2147/CLEP.S9948127822086
   PubMed Web of Science ®Google Scholar
• Stender MT, Frokjaer JB, Larsen TB, Lundbye-Christensen S, Thorlacius-Ussing O. Preoperative plasma D-dimer is a predictor of postoperative deep venous thrombosis in colorectal cancer patients: a clinical, prospective cohort study with one-year follow-up. Dis Colon Rectum. 2009;52(3):446–451. doi:10.1007/DCR.0b013e318197e2b219333044
   PubMed Web of Science ®Google Scholar
• Hansdotter Andersson P, Wille-Jorgensen P, Horvath-Puho E, et al. The COLOFOL trial: study design and comparison of the study population with the source cancer population. Clin Epidemiol. 2016;8:15–21. doi:10.2147/CLEP.S9266126869813
   PubMed Web of Science ®Google Scholar
• Gjerstorff ML. The Danish cancer registry. Scand J Public Health. 2011;39(7 Suppl):42–45. doi:10.1177/140349481039356221775350
   PubMed Web of Science ®Google Scholar
• Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sorensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449–490. doi:10.2147/CLEP.S9112526604824
   PubMed Web of Science ®Google Scholar
• Erichsen R, Lash TL, Hamilton-Dutoit SJ, Bjerregaard B, Vyberg M, Pedersen L. Existing data sources for clinical epidemiology: the Danish National Pathology Registry and Data Bank. Clin Epidemiol. 2010;2:51–56. doi:10.2147/CLEP.S990820865103
   PubMedGoogle Scholar
• Fayers PM, Ashby D, Parmar MK. Tutorial in biostatistics Bayesian data monitoring in clinical trials. Stat Med. 1997;16(12):1413–1430. doi:10.1002/(SICI)1097-0258(19970630)16:12<1413::AID-SIM578>3.0.CO;2-U9232762
   PubMed Web of Science ®Google Scholar
• Hassett MJ, Ritzwoller DP, Taback N, et al. Validating billing/encounter codes as indicators of lung, colorectal, breast, and prostate cancer recurrence using 2 large contemporary cohorts. Med Care. 2014;52(10):e65–73. doi:10.1097/MLR.0b013e318277eb6f23222531
   PubMed Web of Science ®Google Scholar
• McClish D, Penberthy L, Pugh A. Using Medicare claims to identify second primary cancers and recurrences in order to supplement a cancer registry. J Clin Epidemiol. 2003;56(8):760–767. doi:10.1016/S0895-4356(03)00091-X12954468
   PubMed Web of Science ®Google Scholar